Jupiter Neurosciences (JUNS) financial statements
Jupiter Neurosciences reported revenue of $21,796 in fiscal 2025.
Net income was -$9M.
The diluted share count rose 31% over the period (dilution).
Revenue and free cash flow
Fiscal years, $ billions.
Income statement
Fiscal years, from Jupiter Neurosciences's 10-K filings with the SEC.
| Fiscal year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | — | $0 | $21,796 |
| Cost of revenue | — | — | $4,231 |
| Gross profit | — | — | $17,565 |
| Research and development | $954,793 | $492,660 | $2M |
| Selling, general and admin | $3M | $3M | $7M |
| Operating income | -$4M | -$3M | -$9M |
| Interest expense | $218,705 | $248,366 | $66,020 |
| Net income | -$5M | -$2M | -$9M |
| EPS (diluted) | -$0.18 | -$0.08 | -$0.25 |
| Diluted shares | 26M | 29M | 35M |
| Gross margin | — | — | 80.6% |
| Operating margin | — | — | -40873.2% |
| Net margin | — | — | -39662.8% |
Balance sheet
Fiscal years, from Jupiter Neurosciences's 10-K filings with the SEC.
| Fiscal year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Cash and short-term investments | $28,478 | $4M | $4M |
| Receivables | — | — | $2,637 |
| Inventory | — | — | $159,790 |
| Total current assets | $28,739 | $5M | $5M |
| Total assets | $148,592 | $6M | $6M |
| Total current liabilities | $6M | $2M | $7M |
| Total liabilities | $6M | $2M | $7M |
| Shareholders' equity | -$6M | $4M | -$2M |
| Net debt | -$28,478 | -$4M | -$4M |
Cash flow
Fiscal years, from Jupiter Neurosciences's 10-K filings with the SEC.
| Fiscal year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Operating cash flow | -$480,953 | -$4M | -$5M |
| Stock-based compensation | $1M | $2M | $2M |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for JUNS.
Open JUNS in InvestinglyQuestions
What was Jupiter Neurosciences's revenue in 2025?
$21,796 in fiscal 2025, from its 10-K filing.
From Jupiter Neurosciences's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.